Cardiac decompensation of patients before transcatheter aortic valve implantation-clinical presentation, responsiveness to associated medication, and prognosis.

Cardiac decompensation (CD) in patients with aortic stenosis is a "red flag" for future adverse events. We classified patients undergoing transcatheter aortic valve implantation (TAVI) into those with acute, prior, or no prior CD at the timepoint of TAVI and compared their clinical presentation, prognosis, and effects of the prescribed medication during follow-up. Retrospective analysis of patients of one center fulfilling the criteria of 30-day device success after transfemoral TAVI. From those patients with no CD ( The clinical presentation of (acute or prior) cardiac decompensation in patients with AS overlapped substantially with that of patients with classical signs of heart failure. Our results may support an early treatment strategy in patients with left ventricular dysfuntion before clinical signs of congestion are manifest. Moreover, these patients require intensive medical attention after TAVI.

Informations de copyright

© 2023 Fischer-Rasokat, Renker, Charitos, Strunk, Treiber, Rolf, Weferling, Choi, Hamm and Kim.

Déclaration de conflit d'intérêts

UF-R: none. EC: proctor fees from Boston Scientific. MR: speaker fees from St. Jude Medical/Abbott. CS: none. JT: none. AR: none. MW: speaker fees from Boston Scientific. Y-HC: proctor/speaker/scientific advisor fees from Getinge, Jotec/CryoLife, Cytosorbents. CH: advisory board Medtronic. W-KK: proctor/speaker fees from Abbott, Boston Scientific, Edwards Lifesciences, Medtronic, Meril Life Sciences, Shockwave Medical.